5-FU/cisplatin

DRUG2 trials

Sponsors

Taiho Oncology, Inc., University of Erlangen-Nürnberg Medical School

Conditions

Gastric CancerHead and Neck Cancer

Phase 3

A Safety and Efficacy Study in Patients With Gastric Cancer

CompletedNCT00400179

Taiho Oncology, Inc.Gastric Cancer

Start: 2005-05-31End: 2008-04-30Updated: 2024-09-19

Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer

TerminatedNCT01126216

University of Erlangen-Nürnberg Medical SchoolHead and Neck Cancer

Start: 2010-06-30End: 2019-06-30Updated: 2021-05-04

Related Papers

Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial.

2020-02-0728 citations

Randomised phase-III-trial of concurrent chemoradiation (CRT) for locally advanced head and neck cancer (stage III-IVB): Comparing dose reduced radiotherapy (63,6 Gy) with paclitaxel/cisplatinum to standard radiotherapy (70,6 Gy) with fluorouracil/cisplatinum.

Journal of Clinical Oncology2017-05-205 citations

Identification of patient population with longer survival when treated with S-1 plus cisplatin via predictive enrichment strategy analysis of the FLAGS phase III trial.

Journal of Clinical Oncology2017-05-201 citations